Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.64 |
| ▸ | GPR3 | P46089 | 1/20 | 0.64 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.64 |
| ▸ | GABRP | O00591 | 7/20 | 0.61 |
| ▸ | GABRD | O14764 | 7/20 | 0.61 |
| ▸ | GABRA1 | P14867 | 7/20 | 0.61 |
| ▸ | GABRB1 | P18505 | 7/20 | 0.61 |
| ▸ | GABRG2 | P18507 | 7/20 | 0.61 |
| ▸ | GABRB3 | P28472 | 7/20 | 0.61 |
| ▸ | GABRA5 | P31644 | 7/20 | 0.61 |
| ▸ | GABRA3 | P34903 | 7/20 | 0.61 |
| ▸ | GABRA2 | P47869 | 7/20 | 0.61 |
| ▸ | GABRB2 | P47870 | 7/20 | 0.61 |
| ▸ | GABRA4 | P48169 | 7/20 | 0.61 |
| ▸ | GABRE | P78334 | 7/20 | 0.61 |
| ▸ | GABRA6 | Q16445 | 7/20 | 0.61 |
| ▸ | GABRG1 | Q8N1C3 | 7/20 | 0.61 |
| ▸ | GABRG3 | Q99928 | 7/20 | 0.61 |
| ▸ | GABRQ | Q9UN88 | 7/20 | 0.61 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Carbazole SCHEMBL30209164 | 0.80 | ALDH1A1 (1.00) | ALDH1A1GPR3HSD17B10GABRPGABRD | |
| Carbazole SCHEMBL29355407 | 0.80 | ALDH1A1 (1.00) | ALDH1A1GPR3HSD17B10GABRPGABRD | |
| Carbazole SCHEMBL370524 | 0.80 | ALDH1A1 (1.00) | ALDH1A1GPR3HSD17B10GABRPGABRD | |
| Carbazole SCHEMBL29627417 | 0.80 | ALDH1A1 (1.00) | ALDH1A1GPR3HSD17B10GABRPGABRD | |
| Carbazole SCHEMBL30761795 | 0.80 | ALDH1A1 (1.00) | ALDH1A1GPR3HSD17B10GABRPGABRD | |
| Carbazole SCHEMBL26134117 | 0.80 | ALDH1A1 (1.00) | ALDH1A1GPR3HSD17B10GABRPGABRD | |
| Carbazole SCHEMBL7650 | 0.80 | ALDH1A1 (1.00) | ALDH1A1GPR3HSD17B10GABRPGABRD | |
| Carbazole SCHEMBL23148507 | 0.77 | ALDH1A1 (0.93) | ALDH1A1GPR3HSD17B10GABRPGABRD | |
| Carbazole SCHEMBL25327723 | 0.77 | ALDH1A1 (0.93) | ALDH1A1GPR3HSD17B10GABRPGABRD | |
| Carbazole SCHEMBL23782006 | 0.77 | ALDH1A1 (0.93) | ALDH1A1GPR3HSD17B10GABRPGABRD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 53 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1910379-B1 | CASPASE INHIBITOR PRODRUGS | VERTEX PHARMA (US) | 2011-10-19 | — | — | EP | claimed |
| US-20110144074-A1 | CASPASE INHIBITORS AND USES THEREOF | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-06-16 | — | — | US | claimed |
| US-7879891-B2 | such as (S)-Carbazole-9-carboxylic acid 1-(3a-fluoromethyl-5-oxo-3a,5,6,6a-tetrahydro-furo[3,2-d]oxazol-2-yl)-2-methyl-propyl ester, used for the treatment of diseases related to inflammatory or degenerative conditions | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-02-01 | — | — | US | claimed |
| US-20090215736-A1 | CASPASE INHIBITORS AND USES THEREOF | VERTEX PHARMACEUTICALS, INCORPORATED (US) | 2009-08-27 | — | — | US | claimed |
| US-7442790-B2 | Caspase inhibitors and uses thereof | VERTEX PHARMACEUTICALS, INCORPORATED (US) | 2008-10-28 | — | — | US | claimed |
| EP-1923386-A2 | Carbamate caspase inhibitors and uses thereof | Vertex Pharmceuticals Incorporated (US) | 2008-05-21 | — | — | EP | claimed |
| EP-1910379-A2 | CASPASE INHIBITOR PRODRUGS | Vertex Pharmaceuticals Incorporated (US) | 2008-04-16 | — | — | EP | claimed |
| EP-1268425-B1 | CARBAMATE CASPASE INHIBITORS AND USES THEREOF | VERTEX PHARMA (US) | 2008-01-23 | — | — | EP | claimed |
| US-20080015172-A1 | CASPASE INHIBITORS AND USES THEREOF | VERTEX PHARMACEUTICALS INCORPORATED | 2008-01-17 | — | — | US | claimed |
| US-20070155718-A1 | Caspase inhibitor prodrugs | VERTEX PHARMACEUTICALS INCORPORATED | 2007-07-05 | — | — | US | claimed |
| WO-2007015931-A2 | CASPASE INHIBITOR PRODRUGS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2007-02-08 | — | — | WO | claimed |
| US-7074782-B2 | Carbamate caspase inhibitors and uses thereof | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2006-07-11 | — | — | US | claimed |
| US-20040053920-A1 | Carbamate caspase inhibitors and uses thereof | VERTEX PHARMACEUTICALS INCORPORATED | 2004-03-18 | — | — | US | claimed |
| EP-1392289-A2 | CASPASE INHIBITORS AND USES THEREOF | Vertex Pharmaceuticals Incorporated (US) | 2004-03-03 | — | — | EP | claimed |
| US-20030092703-A1 | Caspase inhibitors and uses thereof | VERTEX PHARMACEUTICALS INCORPORATED | 2003-05-15 | — | — | US | claimed |
| EP-1268425-A2 | CARBAMATE CASPASE INHIBITORS AND USES THEREOF | Vertex Pharmaceuticals Incorporated (US) | 2003-01-02 | — | — | EP | claimed |
| WO-2002094263-A2 | CASPASE INHIBITORS AND USES THEREOF | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2002-11-28 | — | — | WO | claimed |
| US-20020028803-A1 | Carbamate caspase inhibitors and uses thereof | VERTEX PHARMACEUTICALS INCORPORATED | 2002-03-07 | — | — | US | claimed |
| WO-2001072707-A2 | CARBAMATE CASPASE INHIBITORS AND USES THEREOF | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2001-10-04 | — | — | WO | claimed |
| US-10391175-B2 | BET bromodomain inhibitors and therapeutic methods using the same | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2019-08-27 | — | — | US | disclosed |
| EP-2970312-B1 | BET BROMODOMAIN INHIBITORS AND THERAPEUTIC METHODS USING THE SAME | UNIV MICHIGAN REGENTS (US) | 2017-11-15 | — | — | EP | disclosed |
| US-20170281773-A1 | BET BROMODOMAIN INHIBITORS AND THERAPEUTIC METHODS USING THE SAME | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2017-10-05 | — | — | US | disclosed |
| US-9675697-B2 | BET bromodomain inhibitors and therapeutic methods using the same | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2017-06-13 | — | — | US | disclosed |
| US-20170160287-A1 | USE OF 7-CHLORO-N,N,5-TRIMETHYL-4-OXO-3-PHENYL-3,5-DIHYDRO-4H-PYRIDAZINO[4,5-B] INDOLE-1-ACETAMIDE AS A BIOMARKER OF PERIPHERAL BENZODIAZEPINE RECEPTOR LEVELS | SANOFI (FR) | 2017-06-08 | — | — | US | disclosed |
| EP-2970312-A1 | BET BROMODOMAIN INHIBITORS AND THERAPEUTIC METHODS USING THE SAME | The Regents of The University of Michigan (US) | 2016-01-20 | — | — | EP | disclosed |
| WO-2014164596-A1 | BET BROMODOMAIN INHIBITORS AND THERAPEUTIC METHODS USING THE SAME | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2014-10-09 | — | — | WO | disclosed |
| US-20140256706-A1 | BET BROMODOMAIN INHIBITORS AND THERAPEUTIC METHODS USING THE SAME | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2014-09-11 | — | — | US | disclosed |
| EP-2349352-B1 | Use of 7-chloro-N,N,5-trimethyl-4-oxo-3-phenyl-3,5-dihydro-4H-pyridazino[4,5-b]indole-1-acetamide as a biomarker of peripheral benzodiazepine receptor levels | SANOFI SA (FR) | 2013-12-25 | — | — | EP | disclosed |
| US-8168798-B2 | Caspase inhibitor prodrugs | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-05-01 | — | — | US | disclosed |
| US-20120039816-A1 | USE OF 7-CHLORO-N,N,5-TRIMETHYL-4-OXO-3-PHENYL-3,5-DIHYDRO-4H-PYRIDAZINO[4,5-B] INDOLE-1-ACETAMIDE AS A BIOMARKER OF PERIPHERAL BENZODIAZEPINE RECEPTOR LEVELS | SANOFI-AVENTIS (FR) | 2012-02-16 | — | — | US | disclosed |
| EP-1910379-B1 | CASPASE INHIBITOR PRODRUGS | VERTEX PHARMA (US) | 2011-10-19 | — | — | EP | disclosed |
| US-20110144074-A1 | CASPASE INHIBITORS AND USES THEREOF | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-06-16 | — | — | US | disclosed |
| US-20110137037-A1 | CASPASE INHIBITOR PRODRUGS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-06-09 | — | — | US | disclosed |
| US-7879891-B2 | such as (S)-Carbazole-9-carboxylic acid 1-(3a-fluoromethyl-5-oxo-3a,5,6,6a-tetrahydro-furo[3,2-d]oxazol-2-yl)-2-methyl-propyl ester, used for the treatment of diseases related to inflammatory or degenerative conditions | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-02-01 | — | — | US | disclosed |
| US-7875712-B2 | inhibitors of apoptosis and IL-1 beta secretion; mediate cell apoptosis and inflammation; good cell penetration and pharmacokinetic properties; [3S/R(2S)]3-[2-(Carbazol-9-yl-2-oxo-ethyl)-pentanoylamino]-5-fluoro-4-oxo-pentanoic acid | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-01-25 | — | — | US | disclosed |
| EP-2181717-A1 | Use of 7-chloro-N,N,5-trimethyl-4-oxo-3-phenyl-3,5-dihydro-4H-pyridazino[4,5-B]indole-1-acetamide as a biomarker of peripheral benzodiazepine receptor levels | Sanofi-Aventis (FR) | 2010-05-05 | — | — | EP | disclosed |
| US-20090215736-A1 | CASPASE INHIBITORS AND USES THEREOF | VERTEX PHARMACEUTICALS, INCORPORATED (US) | 2009-08-27 | — | — | US | disclosed |
| US-7442790-B2 | Caspase inhibitors and uses thereof | VERTEX PHARMACEUTICALS, INCORPORATED (US) | 2008-10-28 | — | — | US | disclosed |
| EP-1923386-A2 | Carbamate caspase inhibitors and uses thereof | Vertex Pharmceuticals Incorporated (US) | 2008-05-21 | — | — | EP | disclosed |
| US-7351702-B2 | Controlling apoptosis; antiinflammatory agents; autoimmune disease | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2008-04-01 | — | — | US | disclosed |
| EP-1268425-B1 | CARBAMATE CASPASE INHIBITORS AND USES THEREOF | VERTEX PHARMA (US) | 2008-01-23 | — | — | EP | disclosed |
| EP-1268425-B1 | CARBAMATE CASPASE INHIBITORS AND USES THEREOF | VERTEX PHARMA (US) | 2008-01-23 | — | — | EP | disclosed |
| US-20080015172-A1 | CASPASE INHIBITORS AND USES THEREOF | VERTEX PHARMACEUTICALS INCORPORATED | 2008-01-17 | — | — | US | disclosed |
| US-20070155718-A1 | Caspase inhibitor prodrugs | VERTEX PHARMACEUTICALS INCORPORATED | 2007-07-05 | — | — | US | disclosed |
| US-7074782-B2 | Carbamate caspase inhibitors and uses thereof | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2006-07-11 | — | — | US | disclosed |
| US-20040053920-A1 | Carbamate caspase inhibitors and uses thereof | VERTEX PHARMACEUTICALS INCORPORATED | 2004-03-18 | — | — | US | disclosed |
| US-6689784-B2 | CONTROLLING CELL APOPTOSIS | VERTEX PHARMACEUTICALS INCORPORATED | 2004-02-10 | — | — | US | disclosed |
| US-20030092703-A1 | Caspase inhibitors and uses thereof | VERTEX PHARMACEUTICALS INCORPORATED | 2003-05-15 | — | — | US | disclosed |
| EP-1268425-A2 | CARBAMATE CASPASE INHIBITORS AND USES THEREOF | Vertex Pharmaceuticals Incorporated (US) | 2003-01-02 | — | — | EP | disclosed |
| US-20020028803-A1 | Carbamate caspase inhibitors and uses thereof | VERTEX PHARMACEUTICALS INCORPORATED | 2002-03-07 | — | — | US | disclosed |
| WO-2001072707-A2 | CARBAMATE CASPASE INHIBITORS AND USES THEREOF | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2001-10-04 | — | — | WO | disclosed |
| US-5652239-A | TREATMENT OF STROKES, ISCHEMIC ATTACK, ANTAGONISTS OF EXCITATORY AMINO ACIDS GLUTAMATE AND ASPARTATE | IMPERIAL CHEMICAL COMPANY (GB) | 1997-07-29 | — | — | US | disclosed |
| EP-0512817-A1 | Pyridazinedione derivatives, their preparation and pharmaceutical applications | ZENECA LIMITED (GB) | 1992-11-11 | — | — | EP | disclosed |
| EP-0512817-A1 | Pyridazinedione derivatives, their preparation and pharmaceutical applications | ZENECA LIMITED (GB) | 1992-11-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020028803-A1 | Carbamate caspase inhibitors and uses thereof | CASP1, CASP2, CASP3 | ALDH1A1 1692/4885GPR3 1827/4885HSD17B10 705/4885 |
| US-20070155718-A1 | Caspase inhibitor prodrugs | CASP1, CASP5, CASP2 | ALDH1A1 757/4885GPR3 2517/4885HSD17B10 897/4885 |
| US-10391175-B2 | BET bromodomain inhibitors and therapeutic methods using the same | BRD4, BRDT, BRD3 | ALDH1A1 4162/4885GPR3 3937/4885HSD17B10 2887/4885 |
| US-20080015172-A1 | CASPASE INHIBITORS AND USES THEREOF | CASP1, CASP2, CASP9 | ALDH1A1 1417/4885GPR3 1851/4885HSD17B10 526/4885 |
| US-20110144074-A1 | CASPASE INHIBITORS AND USES THEREOF | CASP1, CASP2, CASP9 | ALDH1A1 1317/4885GPR3 1923/4885HSD17B10 389/4885 |
| US-20040053920-A1 | Carbamate caspase inhibitors and uses thereof | CASP1, CASP2, CASP3 | ALDH1A1 1692/4885GPR3 1827/4885HSD17B10 705/4885 |
| US-20110137037-A1 | CASPASE INHIBITOR PRODRUGS | CASP1, CASP5, CASP2 | ALDH1A1 757/4885GPR3 2517/4885HSD17B10 897/4885 |
| US-20170281773-A1 | BET BROMODOMAIN INHIBITORS AND THERAPEUTIC METHODS USING THE SAME | BRD4, BRDT, BRD3 | ALDH1A1 4162/4885GPR3 3937/4885HSD17B10 2887/4885 |
| US-20090215736-A1 | CASPASE INHIBITORS AND USES THEREOF | CASP1, CASP2, CASP9 | ALDH1A1 1317/4885GPR3 1923/4885HSD17B10 389/4885 |
| US-20140256706-A1 | BET BROMODOMAIN INHIBITORS AND THERAPEUTIC METHODS USING THE SAME | BRD4, BRDT, BRD3 | ALDH1A1 4162/4885GPR3 3937/4885HSD17B10 2887/4885 |
| US-20030092703-A1 | Caspase inhibitors and uses thereof | CASP1, CASP2, CASP3 | ALDH1A1 802/4885GPR3 2298/4885HSD17B10 372/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.